라니비주맙: 두 판 사이의 차이

라니비주맙 (원본 보기)

209 바이트 추가됨 , 2022년 2월 16일 (수)

잔글

편집

13,127

번

@@ 49번째 줄: / 49번째 줄: @@
 * [[EXCITE]]
 * [[SUSTAIN]]
-* [[PrONTO]] (Prospective OCT Imaging of Patients with Neovascular AMD Treated with intraOcular Ranibizumab)<ref>Fung AE et al. An OCT-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for wAMD. ''AJO''. 2007 Apr;143(4):566-83. [https://pubmed.ncbi.nlm.nih.gov/17386270/ 연결]</ref>
+* [[PrONTO]] (Prospective OCT Imaging of Patients with Neovascular AMD Treated with intraOcular Ranibizumab)<ref>Fung AE et al. An OCT-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for wAMD. ''AJO''. 2007 Apr;143(4):566-83. [https://pubmed.ncbi.nlm.nih.gov/17386270/ 연결]</ref><ref>Lalwani GA et al. A variable-dosing regimen with intravitreal ranibizumab for wAMD : year 2 of the PrONTO Study. ''AJO''. 2009 Jul;148(1):43-58.e1. [https://pubmed.ncbi.nlm.nih.gov/19376495/ 연결]</ref>
 * [[HORIZON]]<ref>Singer MA et al. HORIZON: an open-label extension trial of ranibizumab for CNV secondary to AMD. ''Ophthalmology''. 2012 Jun;119(6):1175-83. [https://pubmed.ncbi.nlm.nih.gov/22306121/ 연결]</ref>
 * [[SECURE]]
 {{참고}}